Clinical and biochemical features of some intravenous iron complexes

Most anemia cases associated with iron deficiency. There are various therapeutic approaches to compensate iron deficiency. In some cases,
a rapid restore of body iron is required, which is only possible with intravenous administration. Now a number of intravenous iron preparations are available, and each of them has not only advantages. Considering the drugs side effects, there was a need for drugs with high efficiency, low immunogenicity, and minimal toxicity. One of the decisions was to create preparations based on maltose and isomaltose. Such new intravenous iron preparations are ferric carboxymaltose and iron isomaltoside. Currently, there are no available clinical data that isomaltose and maltose preparations differ significantly with respect to adverse reactions associated with their immunogenicity. Based on study results isomaltose preparations in patients with dextran sensibilization should be used with caution. This is not completely exclude the possibility that both of these drugs can be an immune response trigger with a different specificity than the one on dextran develops. Preparations based on maltose, sucrose and gluconate were neutral in immunoprecipitation assay with dextran-reactive antibodies that determines their preference for patients with dextran sensibilisation. Other important properties of ferric carboxymaltose are: convenience of application and lack of oxidative stress that are determined by the slow iron release.

1. Сельчук В.Ю., Чистяков С.С., Толокнов Б.О. и др. Железодефицитная анемия: современное состояние проблемы. Русский мед журн 2012;17:1–7.

2. Jahn M.R., Andreasen H.B., Fütterer S. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (MonoFer®), a new intravenous iron preparation and its clinical implications. Euro J Pharm Biopharm 2011;78:480–91.

3. Crichton R.R., Danielson B.G., Geisser P. Iron therapy with special emphasis on intravenous administration, 3rd ed. Bremen: UNI-MED Verlag, Germany, 2005. P. 83.

4. Моисеев С.В. Железа карбоксимальтозат (Феринжект®) – новый внутривенный препарат для лечения железодефицитной анемии. Клин фармакол и терап 2012;21(2):2–7.

5. Преображенская М.Е. Декстраны и декстраназы. Успехи биологической химии, т. 16. М., 1975. С. 214–235.

6. Bailie G.R., Clark J.A., Lane C.E., Lane P.L. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443–9. 7. Павлов А.Д., Моршакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. Молекулярные и клинические аспекты. М.: ГЭОТАР-Медиа, 2011.

7. Richter A.W., Hedin H.I. Dextran hypersensitivity. Immunol Today 1982;3:132–8.

8. Ljungström K.G., Renck H., Hedin H. et al. Hapten inhibition and dexrtan anaphylaxis Anesthesia 1988;3:729–33.

9. Neiser S., Wilhelm M., Schwarz K. et al. Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay. Port J Nephrol Hypert 2011;25(3):219–24.

10. Инструкция по применению препарата КосмоФер®.

11. McCarthy J.T., Regnier C.E., Loebertmann C.L., Bergstralh E.J. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran – a comparison of two products. Am J Nephrol 2000;20:455–62.

12. Fletes R. Lazarus J.M., Gage J., Chertow G.M. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37:743–9.

13. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dialys Transplant 2004;19:1571–5.

14. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dialys Transplant 2006;21:378–82.

15. Инструкция по медицинскому применению препарата Феринжект®.

16. Geisser Р. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009;23(1):11–6.

17. Инструкция по медицинскому применению препарата МоноФер®.

18. Richter W. Minimal molecular size of dextran required to elicit heterologous passive cutaneous anaphylaxis in guinea pigs. Int Arch Allergy 1972;43:252–68.

19. Messmer K. Risiken der Infusion kolloidaler Losungen. Infusionsther Transfusionsmed 1993;20:284–5.

20. Richter W., Hedin H., Ring J. et al. Anaphylaktoide Reaktionen nac Dextran. Allergologie 1980;3:51–8.

21. Allhoff T., Lenhart F.P. Schwere dextraninduzierte anaphaylaktische/ anaphylaktoide Reaktion (DIAR) trotz Haptenprophylaxe. Infusionsther Transfusion med 1993;20:301–6.